Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.

Leech AO, Vellanki SH, Rutherford EJ, Keogh A, Jahns H, Hudson L, O'Donovan N, Sabri S, Abdulkarim B, Sheehan KM, Kay EW, Young LS, Hill ADK, Smith YE, Hopkins AM.

Breast Cancer Res. 2018 Nov 20;20(1):140. doi: 10.1186/s13058-018-1064-1.

2.

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J.

BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1.

3.

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.

Canonici A, Ivers L, Conlon NT, Pedersen K, Gaynor N, Browne BC, O'Brien NA, Gullo G, Collins DM, O'Donovan N, Crown J.

Invest New Drugs. 2018 Jul 30. doi: 10.1007/s10637-018-0649-y. [Epub ahead of print]

PMID:
30062574
4.

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

Canonici A, Qadir Z, Conlon NT, Collins DM, O'Brien NA, Walsh N, Eustace AJ, O'Donovan N, Crown J.

Invest New Drugs. 2018 Aug;36(4):581-589. doi: 10.1007/s10637-017-0556-7. Epub 2018 Feb 2.

PMID:
29396630
5.

Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cells.

Lucantoni F, Lindner AU, O'Donovan N, Düssmann H, Prehn JHM.

Cell Death Dis. 2018 Jan 19;9(2):42. doi: 10.1038/s41419-017-0039-y.

6.

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.

Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O'Donovan N, O'Connor D, Gallagher WM, Crown J, Fersht AR, Duffy MJ.

Cancer Lett. 2018 Feb 1;414:99-106. doi: 10.1016/j.canlet.2017.09.053. Epub 2017 Oct 22.

PMID:
29069577
7.

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.

Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9.

8.

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.

Collins DM, Gately K, Hughes C, Edwards C, Davies A, Madden SF, O'Byrne KJ, O'Donovan N, Crown J.

Cell Immunol. 2017 Sep;319:35-42. doi: 10.1016/j.cellimm.2017.07.005. Epub 2017 Jul 15.

PMID:
28735814
9.

Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.

McDermott MSJ, Canonici A, Ivers L, Browne BC, Madden SF, O'Brien NA, Crown J, O'Donovan N.

Int J Oncol. 2017 Jun;50(6):2221-2228. doi: 10.3892/ijo.2017.3976. Epub 2017 Apr 26.

PMID:
28498399
10.

Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.

Santra T, Roche S, Conlon N, O'Donovan N, Crown J, O'Connor R, Kolch W.

PLoS One. 2017 May 8;12(5):e0177058. doi: 10.1371/journal.pone.0177058. eCollection 2017.

11.

Vitamin D analogues: Potential use in cancer treatment.

Duffy MJ, Murray A, Synnott NC, O'Donovan N, Crown J.

Crit Rev Oncol Hematol. 2017 Apr;112:190-197. doi: 10.1016/j.critrevonc.2017.02.015. Epub 2017 Feb 22. Review.

PMID:
28325259
12.

Vitamin D receptor as a target for breast cancer therapy.

Murray A, Madden SF, Synnott NC, Klinger R, O'Connor D, O'Donovan N, Gallagher W, Crown J, Duffy MJ.

Endocr Relat Cancer. 2017 Apr;24(4):181-195. doi: 10.1530/ERC-16-0463. Epub 2017 Feb 17.

PMID:
28213567
13.

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?

Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J, Duffy MJ.

Int J Cancer. 2017 Jan 1;140(1):234-246. doi: 10.1002/ijc.30425. Epub 2016 Sep 24.

14.

Validated biomarkers: The key to precision treatment in patients with breast cancer.

Duffy MJ, O'Donovan N, McDermott E, Crown J.

Breast. 2016 Oct;29:192-201. doi: 10.1016/j.breast.2016.07.009. Epub 2016 Aug 9. Review.

PMID:
27521224
15.

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, Young L, Kay EW, O'Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT.

J Natl Cancer Inst. 2016 Jul 4;108(8). pii: djw111. doi: 10.1093/jnci/djw111. Print 2016 Aug. No abstract available.

16.

Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells.

Caiazza F, Murray A, Madden SF, Synnott NC, Ryan EJ, O'Donovan N, Crown J, Duffy MJ.

Endocr Relat Cancer. 2016 Apr;23(4):323-34. doi: 10.1530/ERC-16-0068. Epub 2016 Mar 1.

PMID:
26932782
17.

Impact of Microcalcifications on Risk of Malignancy in Thyroid Nodules with Indeterminate or Benign Cytology.

Brophy C, Stewart J, O'Donovan N, McCarthy J, Murphy M, Sheahan P.

Otolaryngol Head Neck Surg. 2016 Jan;154(1):46-51. doi: 10.1177/0194599815605326. Epub 2015 Sep 21.

PMID:
26392026
18.

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.

Mahgoub T, Eustace AJ, Collins DM, Walsh N, O'Donovan N, Crown J.

Int J Oncol. 2015 Sep;47(3):900-8. doi: 10.3892/ijo.2015.3097. Epub 2015 Jul 21.

19.

Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.

Caiazza F, McGowan PM, Mullooly M, Murray A, Synnott N, O'Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J, Duffy MJ.

Br J Cancer. 2015 Jun 9;112(12):1895-903. doi: 10.1038/bjc.2015.163. Epub 2015 May 26.

20.

Analysis of receptor tyrosine kinase (RTK) phosphorylation by immunoblotting.

McDermott M, O'Donovan N.

Methods Mol Biol. 2015;1233:3-14. doi: 10.1007/978-1-4939-1789-1_1.

PMID:
25319884

Supplemental Content

Loading ...
Support Center